<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728507</url>
  </required_header>
  <id_info>
    <org_study_id>06-0018</org_study_id>
    <nct_id>NCT00728507</nct_id>
  </id_info>
  <brief_title>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</brief_title>
  <official_title>A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although effective therapy for tuberculosis is available, TB continues to cause significant
      problems worldwide, and rates of multi-drug resistant (MDR) TB cases are on the rise. A major
      obstacle to the control of TB is poor adherence with lengthy (usually 6 months) and
      complicated treatment regimens. Incomplete TB treatment can lead to serious consequences such
      as increased severity of illness and death, prolonged infectiousness and transmission in the
      community, and the development of drug resistance. The development of new treatment
      strategies with more stronger drugs could lead to shorter and simpler regimens. A TB
      treatment regimen that allowed treatment duration to be meaningfully decreased would have
      important public health implications.

      This trial will compare the effect and safety of a new oral regimen to that of the standard
      regimen for the first phase of treatment for pulmonary tuberculosis.

      The experimental regimen will consist of the following:

        -  Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered
           once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.

      The standard control intensive phase regimen will consist of the following:

        -  Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once
           daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.

      Following intensive phase therapy (the study phase), all patients will be treated with a
      non-experimental continuation phase regimen.

      In mice, the combination of Moxifloxacin and Rifapentine have cured the animals significantly
      faster than the standard regimen and this study will be the first step to see if the
      potential is also there in humans.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding withdrawn
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.</measure>
    <time_frame>Week 8</time_frame>
    <description>LJ culture conversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Compare the Safety and Tolerability of the 2 Intensive Phase Regimens.</measure>
    <time_frame>Weekly or more frequent</time_frame>
    <description>Study was prematurely terminated and data was not collected for this outcome measure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid</intervention_name>
    <description>Rifapentine:150mg tablets, dose = 300mg for subjects &lt;= 45kg and 450mg for those &gt;45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Priftin, Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid, Rifampin, Pyrazinamide, Ethambutol</intervention_name>
    <description>Administered per standard of care for TB treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presumptive diagnosis of sputum smear-positive pulmonary TB.

          -  Age: ≥18 years

          -  Seven (7) or fewer days of multidrug therapy for TB disease in the preceding 6 months.

          -  Seven (7) or fewer days of fluoroquinolone therapy in the preceding 3 months.

          -  Documentation of HIV infection status.

          -  For HIV seropositive individuals, a CD4 T lymphocyte count of greater than or equal to
             200 cells/mm3.

          -  Documentation of study baseline laboratory parameters done at, or ≤ 14 days prior to
             screening:

               -  AST less than or equal to 2.5 times upper limit of normal.

               -  Total bilirubin level less than 2.5 times upper limit of normal.

               -  Creatinine level less than 2 times upper limit of normal.

               -  Hemoglobin level of at least 8.0 g/dl.

               -  Platelet count of at least 75,000 mm3.

               -  Potassium level of at least 3.5.

               -  Negative pregnancy test (women of childbearing potential).

          -  Karnofsky score of at least 60 (requires occasional assistance but is able to care for
             most of his/her needs).

          -  Male or nonpregnant, nonnursing female.

          -  Provision of informed consent.

        Exclusion Criteria:

          -  CD4 count &lt; 200 cells/cu mm.

          -  Presence of active AIDS-related opportunistic infection (other than TB) or active
             AIDS-related malignancy.

          -  Known intolerance to any of the study drugs.

          -  Concomitant disorders or conditions for which any of the study drugs is
             contraindicated. These include severe hepatic damage, acute liver disease of any
             cause, and acute uncontrolled gouty arthritis.

          -  Inability to take oral medication.

          -  Central nervous system TB.

          -  Pulmonary silicosis.

          -  Current or planned therapy, during study phase (intensive phase of TB treatment), with
             any one or more of the following drugs: quinidine, procainamide, amiodarone, sotalol,
             disopyramide, terfenadine, cisapride, erythromycin, clarithromycin, phenothiazines,
             haloperidol, olanzapine, ziprasidone, tricyclic antidepressants, chronic
             corticosteroids administered either orally or intravenously, chronic
             fluconazole,chronic itraconazole, chronic ketoconazole, oral or intravenous
             tacrolimus, oral or intravenous cyclosporine, HIV protease inhibitor, HIV
             non-nucleoside reverse transcriptase inhibitor.

          -  Concurrent severe and/or uncontrolled medical or psychiatric condition that, in the
             opinion of the investigator, could cause unacceptable safety risks or compromise
             compliance with the protocol.

          -  Unable or unwilling to receive directly observed therapy and/or adhere with follow-up
             (e.g. due to residence remote from the study site).

          -  Refusal of consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Dorman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Referência Professor Hélio Fraga - ENSP - FIOCRUZ</name>
      <address>
        <city>Curicica</city>
        <state>Rio de Janeiro</state>
        <zip>22.780-192</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Posto de Saude Albert Sabin</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20211-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clementio Fraga Filho</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med. 2006 Jul 1;174(1):94-101. Epub 2006 Mar 30.</citation>
    <PMID>16574936</PMID>
  </reference>
  <reference>
    <citation>Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004 Feb 1;169(3):421-6. Epub 2003 Oct 24.</citation>
    <PMID>14578218</PMID>
  </reference>
  <reference>
    <citation>Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004 Nov 15;170(10):1131-4. Epub 2004 Aug 11.</citation>
    <PMID>15306535</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <results_first_submitted>August 3, 2016</results_first_submitted>
  <results_first_submitted_qc>March 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2017</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Rifapentine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HPZM</title>
          <description>Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid: Rifapentine:150mg tablets, dose = 300mg for subjects &lt;= 45kg and 450mg for those &gt;45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.</description>
        </group>
        <group group_id="P2">
          <title>HRZE</title>
          <description>Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Isoniazid, Rifampin, Pyrazinamide, Ethambutol: Administered per standard of care for TB treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HPZM</title>
          <description>Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid: Rifapentine:150mg tablets, dose = 300mg for subjects &lt;= 45kg and 450mg for those &gt;45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.</description>
        </group>
        <group group_id="B2">
          <title>HRZE</title>
          <description>Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Isoniazid, Rifampin, Pyrazinamide, Ethambutol: Administered per standard of care for TB treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="25" upper_limit="48"/>
                    <measurement group_id="B2" value="30" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="B3" value="32" lower_limit="24" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.</title>
        <description>LJ culture conversion</description>
        <time_frame>Week 8</time_frame>
        <population>modified intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>HPZM</title>
            <description>Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid: Rifapentine:150mg tablets, dose = 300mg for subjects &lt;= 45kg and 450mg for those &gt;45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.</description>
          </group>
          <group group_id="O2">
            <title>HRZE</title>
            <description>Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Isoniazid, Rifampin, Pyrazinamide, Ethambutol: Administered per standard of care for TB treatment</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.</title>
          <description>LJ culture conversion</description>
          <population>modified intention to treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Compare the Safety and Tolerability of the 2 Intensive Phase Regimens.</title>
        <description>Study was prematurely terminated and data was not collected for this outcome measure.</description>
        <time_frame>Weekly or more frequent</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HPZM</title>
            <description>Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid: Rifapentine:150mg tablets, dose = 300mg for subjects &lt;= 45kg and 450mg for those &gt;45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.</description>
          </group>
          <group group_id="O2">
            <title>HRZE</title>
            <description>Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Isoniazid, Rifampin, Pyrazinamide, Ethambutol: Administered per standard of care for TB treatment</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Safety and Tolerability of the 2 Intensive Phase Regimens.</title>
          <description>Study was prematurely terminated and data was not collected for this outcome measure.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HPZM</title>
          <description>Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid: Rifapentine:150mg tablets, dose = 300mg for subjects &lt;= 45kg and 450mg for those &gt;45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.</description>
        </group>
        <group group_id="E2">
          <title>HRZE</title>
          <description>Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Isoniazid, Rifampin, Pyrazinamide, Ethambutol: Administered per standard of care for TB treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>change in visual refraction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Dorman</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-1755</phone>
      <email>dsusan1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

